Alnylam Pharmaceuticals (ALNY)
Develops and commercializes RNAi medicines led by the AMVUTTRA-centered TTR franchise.
$247.74
vs last close−3.91 (−1.55%)
Something off on this page? Send us feedback.
Next report
Oct 29, 26
in 36 days
EPS estimate
$1.77
Revenue estimate
$1.43B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported−$0.65−$0.44−$0.51$1.84$0.82$1.51$1.21Pending
Estimate−$0.62−$0.89−$0.54$0.56$1.16$0.87$1.63$1.77
Surprise−4.8%+50.6%+6.2%+228.0%−29.3%+73.2%−25.8%—
RevenueReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$593.2M$594.2M$773.7M$1.25B$1.10B$1.17B$1.29BPending
Estimate$582.6M$585.1M$662.9M$959.4M$1.15B$1.12B$1.32B$1.43B
Surprise+1.8%+1.5%+16.7%+30.2%−4.5%+4.6%−2.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $2.51 | — | — |
| Sep 2028 | $2.73 | — | — |
| Jun 2028 | $2.78 | — | — |
| Mar 2028 | $2.85 | — | — |
| Dec 2027 | $3.31 | — | — |
| Sep 2027 | $2.78 | — | — |
| Jun 2027 | $2.44 | — | — |
| Mar 2027 | $2.14 | — | — |
| Dec 2026 | $2.07 | — | — |
| Oct 2026 | $1.77 | — | — |
| Jul 2026 | $1.63 | $1.21 | −25.8% |
| Apr 2026 | $0.87 | $1.51 | +73.2% |
| Feb 2026 | $1.16 | $0.82 | −29.3% |
| Oct 2025 | $0.56 | $1.84 | +228.0% |
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Aug 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $2.51 | — | — | $2.04B | — | — | — |
| Sep 2028 | $2.73 | — | — | $2.03B | — | — | — |
| Jun 2028 | $2.78 | — | — | $1.98B | — | — | — |
| Mar 2028 | $2.85 | — | — | $1.95B | — | — | — |
| Dec 2027 | $3.31 | — | — | $1.90B | — | — | — |
| Sep 2027 | $2.78 | — | — | $1.82B | — | — | — |
| Jun 2027 | $2.44 | — | — | $1.73B | — | — | — |
| Mar 2027 | $2.14 | — | — | $1.62B | — | — | — |
| Dec 2026 | $2.07 | — | — | $1.56B | — | — | — |
| Oct 29, 2026 | $1.77 | — | — | $1.43B | — | — | — |
| Jul 30, 2026 | $1.63 | $1.21 | −25.8% | $1.32B | $1.29B | −2.4% | −28.3% |
| Apr 30, 2026 | $0.87 | $1.51 | +73.2% | $1.12B | $1.17B | +4.6% | +2.8% |
| Feb 12, 2026 | $1.16 | $0.82 | −29.3% | $1.15B | $1.10B | −4.5% | −4.3% |
| Oct 30, 2025 | $0.56 | $1.84 | +228.0% | $959.4M | $1.25B | +30.2% | −6.7% |
| Jul 31, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 13, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 15, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 23, 2023 | |||||||
| Oct 27, 2022 | |||||||
| Jul 28, 2022 | |||||||
| Apr 28, 2022 | |||||||
| Feb 10, 2022 | |||||||
| Oct 28, 2021 | |||||||
| Aug 3, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 11, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 6, 2020 | |||||||
| Oct 31, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 1, 2019 | |||||||
| Feb 7, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 3, 2018 | |||||||
| Feb 8, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 5, 2017 | |||||||
| Feb 8, 2017 | |||||||
| Nov 2, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 2, 2016 | |||||||
| Feb 11, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 6, 2015 |